Johan AuwerxJohan Auwerx is Professor at the École Polytechnique Fédérale in Lausanne, Switzerland, where he occupies the Nestle Chair in Energy Metabolism. Dr. Auwerx has been using molecular physiology and systems genetics to understand metabolism in health, aging and disease. Much of his work focused on understanding how diet, exercise and hormones control metabolism through changing the expression of genes by altering the activity of transcription factors and their associated cofactors. His work was instrumental for the development of agonists of nuclear receptors - a particular class of transcription factors - into drugs, which now are used to treat high blood lipid levels, fatty liver, and type 2 diabetes. Dr. Auwerx was amongst the first to recognize that transcriptional cofactors, which fine-tune the activity of transcription factors, act as energy sensors/effectors that influence metabolic homeostasis. His research validated these cofactors as novel targets to treat metabolic diseases, and spurred the clinical use of natural compounds, such as resveratrol, as modulators of these cofactor pathways.
Johan Auwerx was elected as a member of EMBO in 2003 and is the recipient of a dozen of international scientific prizes, including the Danone International Nutrition Award, the Oskar Minkowski Prize, and the Morgagni Gold Medal. His work is highly cited by his peers with a h-factor of over 100. He is an editorial board member of several journals, including Cell Metabolism, Molecular Systems Biology, The EMBO Journal, Journal of Cell Biology, Cell, and Science. Dr. Auwerx co-founded a handful of biotech companies, including Carex, PhytoDia, and most recently Mitobridge, and has served on several scientific advisory boards.
Dr. Auwerx received both his MD and PhD in Molecular Endocrinology at the Katholieke Universiteit in Leuven, Belgium. He was a post-doctoral research fellow in the Departments of Medicine and Genetics of the University of Washington in Seattle.
Jean-Claude BünzliJean-Claude Bünzli was born in 1944. He earned a degree in chemical engineering in 1968 and a PhD in 1971 (Swiss Federal Institute of Technology, Lausanne) for his work on the kinetic behaviour of Nb and Ta pentachloride adducts. He spent two years at the University of British Columbia as a teaching postdoctoral fellow (photoelectron spectroscopy) and one year at the Swiss Federal Institute of Technology in Zürich (physical organic chemistry).
Positions
He was appointed assistant-professor at the University of Lausanne in 1974 and started a research program on the spectrochemical properties of f-elements. He was promoted as a full professor of inorganic and analytical chemistry in 1980. He transferred to EPFL in 2001 where he directed the Laboratory of Lanthanide Supramolecular Chemistry until 2010.
From 2009 to 2013, he was World Class University Professor at Korea University (South Korea) helping developing a new research center for photovoltaics. In 20154-2015 he acted as visiting professor at FJIRSM (Fuzhou, Fujian), a laboratory of the Chinese Academy of Sciences.
He presently holds the Dr Kennedy Wong Distinguished Visiting Professorship at Hong Kong Baptist University (3 months/year) and a position as Distinguished Scholar at University of Technology, Sydney (NSW, Australia, 1 month/year).
Administrative and reviewer duties
He acted as the elected Dean of the Faculty of Sciences (1990-1991) and as one of the elected Vice-Rectors of the University (1991-1995), in charge of students' affairs and of research programs in the field of biomedical sciences. He held a position of invited professor at the Université Louis Pasteur, Strasbourg in 1996 and at the Science University of Tokyo in 1998. In 1989, he founded the European Rare Earths and Actinide Society which coordinate international conferences in the field (cf. http://ereswww.epfl.ch).
He served as a World Bank Project Specialist within the framework of the Chinese Provincial Universities Development Project (Northwest China, 1989) and as a member of a Panel in charge of evaluating chemical research at Norwegian universities (1997). In 2001, he was hired as "Peer leader" for the evaluation of the Swiss universities of applied sciences. In 2005, he acted as a member of the "Physical Inorganic Panel" of the Science Foundation of Ireland and in 2006 he was nominated to the "Chemistry Panel" of the same foundation.
He is a member of the Editorial Board of Spectroscopy Letters, associate editor-in-chief of the Journal of Rare Earths, and senior editor of the Handbook on the Physics and Chemistry of Rare Earths (54 volumes published to date).
Teaching
Regarding teaching, he has directed the joint project of the universities of Geneva, Lausanne, Neuchâtel and Fribourg "General chemistry for students enrolled in a life sciences curriculum", within the frame of the "Swiss virtual campus", a program sponsored by the Conference of Swiss universities and the Swiss federal office for science and education (2000-2004). Web site: http://chimge@epfl.ch
Research
His research is centered on lanthanide luminescent molecular and supramolecular edifices, with main applications in biology & medicine. He is the author or the co-author of 350 research papers, 260 contributed communications and has presented 285 invited conferences, seminars, and courses. He has collected >22800 citations (h-index 72). Michel AguetDr. Michel Aguet, MD, held positions in academia and industry (Associate Professor at the Institute of Molecular Biology, University of Zürich; Head of Molecular Oncology, Genentech, So. San Francisco) before he was appointed director of the Swiss Institute for Experimental Cancer Research (ISREC) (1996-2009). In the context of the integration of ISREC into the Swiss Federal Institute of Technology (EPFL), he was appointed as Full Professor at the newly established School of Life Sciences in 2005. From 2001-2013 he directed the National Center of Competence in Research (NCCR) in Molecular Oncology, a national program launched by the Swiss National Science Foundation to encourage translational cancer research and for which ISREC was the leading house. Dr. Aguet has been a SAB member in the pharmaceutical industry, biotech industry and venture capital industry since 1997.
A large part of his scientific career was devoted to exploring the molecular biology of interferons (cloning of the interferon gamma receptor, generation of various interferon signaling mutants in the mouse) and, in collaboration with Prof. Charles Weissmann, to investigating the role of prion related protein PrP in mouse prion disease models. In recent years his research focused on characterizing the role of BCL9 proteins, which are part of the Wnt/beta-catenin transcriptional activation complex, in regulating stem cell traits in intestinal epithelium and colorectal cancer. His laboratory is now closed due to retirement.
Hilal Lashuel2012-2013 Visiting Professor, Standford University. Stanford School of Medicine
2011- Associate Professor of Life Sciences-Brain Mind Institute-EPFL
Dir. Laboratory of Chemical Biology of Neurodegeneration
2005-2011 Assistant Professor of Life Sciences-Brain Mind Institute-EPFL
Dir. Laboratory of Molecular Neurobiology and Neuroproteomics
2005-2008 Director- EPFL Proteomic Core Facility
2002-2004 Instructor of Neurology- Harvard Medical School and Brigham and Women's
Hospital
2001-2002 Sabbatical Fellow- Laboratory for Drug Discovery in Neurodegeneration
Harvard Medical School,
2001-2002 Post-doctoral Fellow- Center for Neurologic Diseases
Harvard Medical School and Brigham and Women's Hospital
Advisor- Prof. Peter T. Lansbury
2000-2001 Research Scientist, The Picower Institute for Medical Research, Great Neck
New York
1994-2000 PhD Student; Texas A&M University and the Scripps Research Institute
Advisor- Prof. Jeffery W. Kelly
1990-1994 B.S. City University of New York, Brooklyn College
Dr. Hilal A. Lashuel received his B.Sc. degree in chemistry from the City University of New York in 1994 and completed his doctoral studies at Texas A&M University and the Scripps Research Institute in 2000. After obtaining his doctoral degree, he became a research fellow at the Picower Institute for Medical Research in Long Island New York. In 2001, he moved to Harvard Medical School and the Brigham and Women's Hospital as a research fellow in the Center for Neurologic Diseases and was later promoted to an instructor in neurology at Harvard Medical School. During his tenure (2001-2004) at Harvard Medical School his work focused on understanding the mechanisms of protein misfolding and fibrillogenesis and the role of these processes in the pathogenesis of Parkinson's and Alzheimer's disease. In 2005 Dr. Lashuel moved Switzerland to join the Brain Mind Institute at the Swiss Federal Institute of Technology Lausanne as a tenure-track assistant professor in neurosciences. Currently, Dr. Lashuel is an associate professor of life sciences and the director of the laboratory of molecular and chemical biology of neurodegeneration. (http://lashuel-lab.epfl.ch/).
Research efforts in the Lashuels laboratory focus on understanding the molecular mechanisms of neurodegeneration and developing novel strategies to diagnose and treat neurodegenerative diseases such as Alzheimers and Parkinsons disease. Research in the Lashuel lab is funded by several international funding agencies and foundations, including the Swiss National Science Foundation, European FP7 program (Marie Curie and ERC grants), Human Science Frontiers, Strauss Foundation, Cure the Huntingtons disease foundation and Michael J Fox foundation and is supported by collaborations with pharmaceutical and biotech companies (http://lashuel-lab.epfl.ch/page-50538-en.html), Nestle, Merck-Serono, AC Immune and Johnson and Johnson.
Dr. Lashuels research has resulted in the characterization of novel quaternary structure intermediates on the amyloid pathway, identification of potential therapeutic targets, and new hypotheses concerning the mechanisms of pathogenesis in Alzheimers disease, Parkinsons disease and related disorders. Dr. Lashuel scientific contribution to this field includes i) more than100 publications in major peer reviewed journals including Nature journals, Cell, PNAS, JBC, J. Neuroscience JACS, and Angewandtie Chemie; ii) three patents on novel strategies for preventing protein aggregation and treating autoimmune and inflammatory diseases; iii) more than 150 invited lectures since 2002 and more than 5500 citations (7800 citation-Google Scholar) since 1996. Dr. Lashuel has received several pre-doctoral and post-doctoral awards and fellowships and was the recipient of two prestigious awards given to young investigators; Human Science Frontiers young investigator research award and the European Research Council (ERC) starting independent researcher grant and the ERC proof of concept award (2013) These awards provide more than $2.5 Million to Dr. Lashuel to translate some of his ideas and projects into novel strategies for diagnosing and treating neurodegenerative diseases such as Alzheimers and Parkinsons disease. Dr. Lashuel has chaired and co-organized several international conferences and serves as an academic editor for PLoS ONE, an associate editor for frontiers of molecular neuroscience, member of the Editorial advisory board of ChemBioChem and ad hoc reviewer for several international scientific journals and funding agencies. Sandrine GerberSandrine Gerber studied chemistry at the "Ecole Nationale Supérieure de Chimie de Paris" in France, where she obtained a diploma of chemical engineer in 1993. The same year she obtained a DEA (Master degree) of organic chemistry at the University Pierre et Marie Curie (Paris VI, France). From 1993 to 1996 she did a PhD in organic chemistry under the supervision of Prof. Jean-Pierre Genêt at the Ecole Nationale Supérieure de Chimie de Paris. In 1996, she moved to University of Lausanne for a post-doctoral stay under the supervision of Prof. Pierre Vogel. In 1998, she was appointed Maître-Assistante at the Institute of Organic Chemistry in the University of Lausanne. In 2003, she obtained the habilitation to direct research from the University Pierre et Marie Curie (Paris VI, France). The same year, she was appointed scientific adjunct at the EPFL and senior scientist (Maître d'Enseignement et de Recherche) in 2006. In December 2014, she was promoted to titular professor. Since September 2007, Sandrine Gerber is deputy to the director of the Institute of Chemical Sciences and Engineering (ISIC). She is also member of the Board of Directors of the Swiss Chemical Society. Since 2007, Sandrine Gerber is part-time lecturer at the university of Fribourg. She was awarded the Prize Eugene Schueller in 1997, the Prize Dufour for prospective organic chemistry in 2005 and the Werner Prize 2010. She also received a special mention in recognition of exceptional quality of pedagogic competencies in the teaching of basic sciences, given by the Direction of the School of Biology and Medicine from the University of Lausanne, in 2013. In October 2018, she will receive the Prize for Excellence in Teaching from the section of Chemistry and Chemical Engineering.
Heinrich HofmannOriginaire de Mellingen (AG), Heinrich Hofmann est né en 1953. Après des études d'ingénieur en soudures (Ing. grad.) à Duisburg (D), et d'ingénieur en science des matériaux à la Technische Hochschule de Berlin, il obtient le titre de docteur ingénieur en 1983 pour une thèse dans le domaine des matériaux.De 1983 à 1985, il travaille comme assistant scientifique au Laboratoire de Technologie des Poudres de l'Institut Max Planck pour la science des matériaux à Stuttgart. En 1985 il entre au Centre de Recherche et Développement d'Alusuisse-Lonza à Neuhausen-am-Rheinfall, en tant qu'ingénieur consacré à la recherche dans l'étude et le développement des procédés de synthèse des poudres céramiques.En 1993 il entre à l'EPFL en tant que professeur extraordinaire et directeur du Laboratoire de technologie des poudres du Départmeent des matériaux. Son enseignement porte sur les céramiques I (procédés) et les phénomènes de transfert. Son domaine de recherche couvre la synthèse des poudres minérales, leur caractérisation et la modification des surfaces, ainsi que la mise en forme et le frittage. Ses recherches incluent aussi les matériaux nanostructurés (composites semi-conducteurs et polymères) et la métallurgie des poudres. Hofmann Heinrich, Prof. Dr.-Ing. got his PhD in Material Science with a thesis prepared at the Powder Metallurgy Laboratory at the Max Planck Institute in Stuttgart. In 1985 he joins the R&D center of Alusuisse-Lonza Services AG, at Neuhausen-am-Rheinfall. In 1993 he joins the Swiss Federal Institute of Technology as Professor and Director of the Powder Technology Laboratory at the Department of Materials science and engineering. His research area includes the synthesis of nanostructured materials based on nanoparticles and the modification of surfaces with nanoparticles using colloidal methods. The fields of application of such materials are medical and biological, (drug delivery, hyperthermia, cell separation, biosensors), electronics and sensors.
Patrick AebischerPatrick Aebischer a achevé une formation en Médecine (1980) et en Neurosciences (1983) aux Universités de Genève et de Fribourg en Suisse.
De 1984 à 1992, Patrick Aebischer a travaillé à Brown University (USA) au sein du Département des Neurosciences et au Département des Biomatériaux et des Organes Artificiels en tant que Professeur assistant, puis Professeur associé.
En 1992, Patrick Aebischer a été nommé Professeur de la Division Autonome de Recherche Chirurgicale et du Centre de Thérapie Génique (DARC) au Centre Hospitalier Universitaire Vaudois (CHUV) à Lausanne.
En 1999, Le Conseil Fédéral a nommé Patrick Aebischer en tant que Président de l'Ecole Polytechnique Fédérale de Lausanne (EPFL). Il a pris ses fonctions à la Présidence de lEPFL en mars 2000, position qu'il a occupée jusqu'au 31 décembre 2016.
Patrick Aebischer est membre de maintes sociétés professionnelles, tant en Europe quaux Etats-Unis.
Patrick Aebischer a fondé trois start-up de biotechnologies. Il siège au conseil d'administration de Lonza, de Logitech et de Nestlé. Il préside également l'advisory board du Novartis Venture Fund. Patrick Aebischer est membre du conseil de fondation du Festival de Jazz de Montreux, du Festival de Verbier et de la Fondation Jacobs.
Les recherches quil poursuit actuellement dans son laboratoire se concentrent sur le développement d'approches de thérapie cellulaire et de transfert génique pour le traitement des maladies neurodégénératives.
Dominique PiolettiDominique Pioletti received his Master in Physics from the Swiss Federal Institute of Technology Lausanne (EPFL) in 1992. He pursued his education in the same Institution and obtained his PhD in biomechanics in 1997. He developed original constitutive laws taking into account viscoelasticity in large deformations. Then he spent two years at UCSD as post-doc fellow acquiring know-how in cell and molecular biology. He was interested in particular to gene expression of bone cells in contact to orthopedic implant. In April 2006, Dominique Pioletti was appointed Assistant Professor tenure-track at the EPFL and is director of the Laboratory of Biomechanical Orthopedics. His research topics include biomechanics and tissue engineering of musculo-skeletal tissues; mechano-transduction in bone; development of orthopedic implant as drug delivery system. Since 2013, he has been promoted to the rank of Associate Professor.
